International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia.
The treatment, referred to as CT-155, will be a mobile app built on Click’s proprietary tech platform, the companies said … With this big ticket deal, Boehringer Ingelheim becomes the latest major pharma company to bet big on what many in the industry still consider to be an unexplored treatment modality. Of note, the company said in the announcement that its viewing the digital therapeutic as “a meaningful new treatment category” for neuropsychiatric disorders such as schizophrenia. Either alone or with a drug, they wrote, this type of approach could potentially improve access to the kind of tailored psychosocial interventions that are recommended in treatment guidelines for schizophrenia, but infrequently delivered.
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia (press release):
Boehringer Ingelheim and Click Therapeutics today announced they have entered into a collaboration for the development and commercialization of a prescription-based digital therapeutic. It will utilize cognitive and neurobehavioral mechanisms delivered through Click’s proprietary engagement platform with the goal of reducing cognitive deficits and impaired social functioning in patients with schizophrenia. Together the two companies will join their expertise to develop a novel mobile application, CT-155, which combines multiple clinically validated therapeutic interventions to help schizophrenia patients modify their behavior to achieve positive clinical outcomes alone and in combination with pharmaceutical therapy options … “CT-155 is an excellent addition to our CNS pipeline portfolio; it reflects our patient centric approach and translates evidence showing how behavioral modification can induce positive neuronal changes into a widely accessible solution. Further it has the potential to be prescribed together with Boehringer Ingelheim’s schizophrenia pipeline compounds possibly enhancing the benefit of pharmacotherapy for patients,” added Cornelia Dorner-Ciossek, Ph.D., Director CNS Diseases Research at Boehringer Ingelheim.
… Under the terms of the partnership agreement, Click Therapeutics will be primarily responsible for research and development activities, and will support Boehringer Ingelheim as it undertakes worldwide commercialization activities. Click Therapeutics will receive under the terms of the partnership agreement an upfront payment and funding for research and development activities as well as clinical, regulatory and commercial milestones representing a total deal value of over USD 500 million. Additionally, Click Therapeutics will receive tiered royalties on annual net sales of CT-155 worldwide.
The Announcement in Context:
- Sanofi Ventures leads $17M investment in Click Therapeutics
- Otsuka Pharma and Click Therapeutics enter partnership poised to transform mental healthcare
- 10 neurotechnologies about to transform brain enhancement and brain health
- Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright